Wells Fargo has recently downgraded its investment rating for cell therapy company ARCELLX, INC. from "Overweight" to "Equal Weight".
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Oil prices drop and Federal Reserve’s “cooling” rate hikes ease inflation fears, gold regains its footing above the 100-day moving average
At the end of a volatile week, international gold prices held onto their gains as the US Federal Reserve raised interest rates for the first time since 2023 and falling oil prices helped ease market concerns about inflation.
Industry doubts Democrats’ effort to restart talks on stalled CLARITY Act: ‘It’s all talk!’
Bearish to 159! Ahead of Friday's Bank of Japan decision, Wall Street strategists collectively bet on a weaker yen
The swap market has fully priced in expectations of a Bank of Japan rate hike. Strategists warn that if the central bank's hawkish stance falls short of estimates, it could trigger a sell-off in the yen, with the exchange rate potentially dipping towards the 159 level in the short term.
Iran’s IRGC claims attack on Togolese oil tanker for 'illegal transit' in Strait of Hormuz
Crypto prices
More
